Key result
Six months of rilmenidine monotherapy significantly increased plasma adiponectin concentration from 12.5 to 16.9 (P=0.0002) in patients with essential hypertension.
Why the study?
Does rilmenidine increase plasma adiponectin concentration in patients with essential hypertension?
Does rilmenidine increase plasma adiponectin concentration in patients with essential hypertension?
Antihypertensive therapy with rilmenidine for 6 months significantly increases plasma adiponectin concentration in patients with essential hypertension, without altering insulin sensitivity or body fat.
Rilmenidine may raise adiponectin in essential hypertension; hypothesis-generating for metabolic effects, needs randomized confirmation before practice change.
BACKGROUND: Adiponectin is an adipose tissue-specific protein with antiatherogenic and insulin-sensitizing properties. In patients with essential hypertension plasma adiponectin levels are lower than in healthy subjects. It is hypothetized that low plasma adiponectin concentration may be involved in the pathogenesis of vascular complications in hypertension. The aim of the study was to evaluate the effect of 6 months of antihypertensive therapy with rilmenidine on plasma adiponectin concentration in patients with essential hypertension. METHODS: In 20 patients with essential hypertension (mean age 39 +/- 14 years; 11 F, 9 M; mean duration of hypertension 8 +/- 9 years) plasma adiponectin concentration (ELISA; B-Bridge International, San Jose, CA), insulin sensitivity (metabolic clearance of glucose-M value and M/plasma insulin ratio) by the euglycemic-hyperinsulinemic glucose clamp technique, and body fat content (DEXA) were estimated twice, before and after 6 months of antihypertensive monotherapy with rilmenidine (daily dose 1 to 2 mg). RESULTS: The 6 months of treatment with rilmenidine resulted in a significant decrease of systolic (P = .007), diastolic (P = .002), and mean arterial blood pressure (P = .002), no significant change of body mass index (27.7 +/- 4.7 and 27.6 +/- 4.4 kg/m(2)), total body fat content (25.4 +/- 7.3 and 24.9 +/- 6.8 kg), and insulin sensitivity parameters (M value 6.0 +/- 2.5 and 5.8 +/- 4.3 mg/kg/min and M/plasma insulin ratio 7.4 +/- 5.0 and 6.9 +/- 4.3 mg/kg/min/mU/L). However after 6 months of treatment with rilmenidine a significant increase in plasma adiponectin concentration (from 12.5 +/- 6.1 to 16.9 +/- 11.1; P = .0002) was observed. CONCLUSIONS: Antihypertensive therapy with rilmenidine correlates with an increase of plasma adiponectin concentration without any significant changes of insulin sensitivity and body fat content in patients with essential hypertension.
No takes yet. Share an insight, caveat, or question.
Nowak et al. (2005) studied Essential hypertension (n=20). Rilmenidine vs. Baseline was evaluated on Plasma adiponectin concentration (p=0.0002). Six months of rilmenidine monotherapy significantly increased plasma adiponectin concentration from 12.5 to 16.9 (P=0.0002) in patients with essential hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: